Skip to main content
TELA
NASDAQ Industrial Applications And Services

TELA Bio Ousts CEO Antony Koblish, Appoints Heather Getz with Aggressive Equity Package

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$0.73
Mkt Cap
$33.127M
52W Low
$0.501
52W High
$2.14
52W Position info
46% above low
Off High info
66% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

TELA sits 46% above its 52-week low of $0.501.

Summary

TELA Bio fired CEO Antony Koblish and appointed Heather Getz, granting her an equity package equal to ~6.3% of outstanding shares with a Top-Up provision to maintain 5% ownership post-financing, as the company battles financial distress.


Key Events · Executive and Board Changes · TELA

  • CEO Termination

    Antony Koblish removed as CEO and resigned from the Board effective August 3, 2026; termination treated as without cause.

  • New CEO Appointment

    Heather Getz appointed CEO and Class II director; brings 25+ years of healthcare turnaround experience, including growing BioTelemetry from $50M to $2.8B market cap.

  • Compensation Package

    Getz Employment Agreement: $650,000 base salary, 100% target bonus, severance up to 18 months upon change of control termination.

  • Initial Equity Grants

    Granted 1,365,000 standard options (exercise at closing price on grant date), 1,005,000 premium options (exercise at greater of $0.90 or 15% premium to FMV), and 500,000 RSUs, vesting over 4 years.


Analysis · TELA · Industrial Applications And Services

TELA Bio abruptly terminated CEO Antony Koblish and replaced him with Heather Getz, a seasoned healthcare executive. The move comes as the company faces severe financial distress—negative stockholders' equity, a Nasdaq delisting notice, and a stock price near $0.73. Getz's employment agreement includes a $650,000 salary, a 100% target bonus, and an initial equity grant of 2.87 million shares in options and RSUs, representing roughly 6.3% of the current outstanding shares. A Top-Up provision guarantees her additional grants to maintain 5% ownership after any future financing, aligning her incentives with a turnaround but also signaling potential dilution ahead. The leadership change is a high-stakes bet on Getz's track record of turning around distressed medical device companies.

At the time of this filing, TELA was trading at $0.73 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $33.1M. The 52-week trading range was $0.50 to $2.14. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TELA - Latest Insights

TELA
Jun 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
TELA
Jun 09, 2026, 6:29 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
TELA
May 13, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
9
TELA
May 12, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
TELA
May 12, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8